Teva Reports FDA Approval for Degevma

04:25 PM EDT, 09/28/2026 (MT Newswires) -- Teva Pharmaceutical Industries (TEVA) said late Monday the US Food and Drug Administration has approved Degevma as a biosimilar to Xgeva. Degevma is indicated for the prevention of bone complications in adults with advanced cancer that has spread to the bone, it said. The drug is also indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone and for the treatment of hypercalcemia of malignancy, Teva said. Teva said it expects to launch Degevma and Ponlimsi in the US in the coming months. Ponlimsi was approved in March.